Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Protocol to Obtain Blood Samples for Leukemia Research

This study has suspended participant recruitment.
(Review of study records)
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center Identifier:
First received: April 24, 2009
Last updated: November 19, 2014
Last verified: October 2014

The purpose of this study is to collect a blood sample in patients with Chronic Lymphocytic Leukemia (CLL).

Condition Intervention
Chronic Lymphocytic Leukemia
Other: No Intervention

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Protocol to Obtain Blood Samples for Leukemia Research

Resource links provided by NLM:

Further study details as provided by Dartmouth-Hitchcock Medical Center:

Primary Outcome Measures:
  • To determine the frequency with which CLL cells incubated ex vivo with vincristine undergo rapid interphase apoptosis. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To determine whether suppression or inhibition of BCL2 family members can acutely sensitize CLL cells to vincristine. [ Time Frame: 2 Years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

10cc of peripheral blood.

Estimated Enrollment: 50
Study Start Date: April 2009
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
No Treatment Other: No Intervention
Patients with Chronic Lymphocytic Leukemia (CLL)
Other Name: No Intervention

Detailed Description:

The blood sample will be used in the laboratory to perform studies focusing on Chronic Lymphocytic Leukemia (CLL).


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients at Dartmouth-Hitchcock Medical Center's Norris Cotton Cancer Center


Inclusion Criteria:

  • Patients undergoing routine blood draws as part of their ongoing follow-up for Chronic Lymphocytic Leukemia (CLL) at the Norris Cotton Cancer Center of DHMC.

Exclusion Criteria:

  • Patients who have received cytotoxic drug, oral or intravenous steroid or targeted antibody therapy for CLL or other disease process within the past 6 months are excluded. Use of intravenous immunoglobulin (IVIg) is not a reason for exclusion.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00889031

United States, New Hampshire
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Principal Investigator: Christopher H Lowrey, MD Dartmouth-Hitchcock Medical Center
  More Information

Responsible Party: Dartmouth-Hitchcock Medical Center Identifier: NCT00889031     History of Changes
Other Study ID Numbers: D0905
Study First Received: April 24, 2009
Last Updated: November 19, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Dartmouth-Hitchcock Medical Center:

Additional relevant MeSH terms:
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Lymphoid
Immune System Diseases
Immunoproliferative Disorders
Leukemia, B-Cell
Lymphatic Diseases
Lymphoproliferative Disorders
Neoplasms by Histologic Type processed this record on November 19, 2014